Met Life Investment Management, LLC Curis Inc Transaction History

Met Life Investment Management, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.71 - $2.43 $7,190 - $24,611	-10,128 Closed	0 $0
Q1 2022 May 10, 2024	BUY	$2.31 - $5.13 $23,395 - $51,956	10,128 New	10,128 $24,000
Q1 2022 Jun 20, 2023	BUY	$2.31 - $5.13 $23,395 - $51,956	10,128 New	10,128 $24,000
Q1 2022 Mar 22, 2023	SELL	$2.31 - $5.13 $52,423 - $116,420	-22,694 Reduced 69.14%	10,128 $24,000
Q1 2022 May 12, 2022	SELL	$2.31 - $5.13 $52,423 - $116,420	-22,694 Reduced 69.14%	10,128 $24,000
Q4 2021 May 17, 2024	BUY	$4.45 - $8.09 $41,153 - $74,816	9,248 Added 39.23%	32,822 $156,000
Q4 2021 Jun 21, 2023	BUY	$4.45 - $8.09 $146,057 - $265,529	32,822 New	32,822 $156,000
Q4 2021 Mar 22, 2023	BUY	$4.45 - $8.09 $41,153 - $74,816	9,248 Added 39.23%	32,822 $156,000
Q4 2021 Feb 15, 2022	BUY	$4.45 - $8.09 $41,153 - $74,816	9,248 Added 39.23%	32,822 $156,000
Q3 2021 May 17, 2024	SELL	$6.94 - $8.85 $67,921 - $86,614	-9,787 Reduced 29.34%	23,574 $184,000
Q3 2021 Jun 21, 2023	BUY	$6.94 - $8.85 $163,603 - $208,629	23,574 New	23,574 $184,000
Q3 2021 Mar 22, 2023	SELL	$6.94 - $8.85 $67,921 - $86,614	-9,787 Reduced 29.34%	23,574 $184,000
Q3 2021 Nov 15, 2021	SELL	$6.94 - $8.85 $67,921 - $86,614	-9,787 Reduced 29.34%	23,574 $185,000
Q2 2021 May 17, 2024	BUY	$7.45 - $16.27 $248,539 - $542,783	33,361 New	33,361 $269,000
Q2 2021 Jun 21, 2023	BUY	$7.45 - $16.27 $248,539 - $542,783	33,361 New	33,361 $269,000
Q2 2021 Mar 22, 2023	BUY	$7.45 - $16.27 $248,539 - $542,783	33,361 New	33,361 $269,000
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $248,539 - $542,783	33,361 New	33,361 $269,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.